Eradication
Conditions
Brief summary
Helipyl is on the market; actually it is a post-biotic because it is a killed Lactobacillus reuteri DSMZ 17648. The aim is to demonstrate (or not) that this product eradicates helicobacter, which it claims to do.
Detailed description
This is a pilot project. There is quite limited literature on this product and Helicobacter pylori eradication. My personal opinion is that the literature and guidelines are contradictory. The European guideline is that Helicobacter pylori should not be corrected unless there are serious symptoms . On the other hand, Helicobacter is a carcinogen. Quite often, parents ask us, children's gastroenterologists, to screen their children for Helicobacter because they are symptomatic and are being eradicated, and know that Helicobacter is contagious. This creates a difficult situation: not answering the question is not an option according to the parents' opinion. Going into the question and eradicating classic is against all guidelines. Hence this pilot project: 10 complaints-free carriers of Helicobacter pylori (\> 5 years) will be treated with Helipyl for one month (product supplied by the company). Beforehand, at the end of the treatment and a month after stopping of the treatment, we do a C13 breath test.
Interventions
OTHERlactobacillus reuteri DSMZ 17648
to evaluate if this product can eradicate helicobacter pylori
Sponsors
Universitair Ziekenhuis Brussel
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
helipyl is given to patients with non symptomatic helicobacter pylori infection
Eligibility
Sex/Gender
ALL
Age
5 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* \>5 and \<18 years * male and female * asymptomatic helicobacter pylori
Exclusion criteria
* helicobacter pylori infection with symptoms * \<5 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| to evaluate the C13 breathtest | 6months | evaluation of C13 breathtest before, at the end of treatment and one month after treatment |
Countries
Belgium
Outcome results
None listed